Answers are grounded in this paper and cite their sources.
Post-traumatic stress disorder (PTSD) can develop following exposure to a traumatic event and is characterized by the presentation of symptoms across four symptom clusters: intrusion (re-experiencing), avoidance, negative cognitions and mood, and alterations in arousal and reactivity. Post-traumatic stress disorder is associated with a considerable clinical, humanistic, and economic burden. There are only two approved pharmacological treatments for PTSD in the USA and certain European countries: the selective serotonin reuptake inhibitors, sertraline and paroxetine (approvals vary by country). Off-label and non-evidence-based treatments are frequently used in an attempt to address the spectrum of PTSD symptoms. Understanding the biological basis of PTSD can aid in understanding the efficacy and safety profiles of current on-label and off-label treatments for PTSD and is key to the development of effective treatment approaches. The aim of this article is to review the rationale, mechanisms of action, efficacy on diagnostic PTSD symptoms, and safety of drugs targeting monoamine dysregulation in PTSD. Research has indicated that dysregulation of norepinephrine (also known as noradrenaline), serotonin, and dopamine signaling may contribute to the presentation of PTSD symptoms across all four symptom clusters and impact the fear, stress, and reward processes. The monoamine system underlies several on-label and off-label pharmacological treatment approaches in PTSD, including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and atypical antipsychotics. Sertraline and paroxetine, together with off-label venlafaxine, have the greatest evidence for efficacy. Off-label risperidone and brexpiprazole have been studied in a large number of participants, with mixed results. By considering the unique monoamine receptor binding profiles of individual treatments, it may be possible to understand the mechanistic basis behind differences in the clinical profiles of each agent in the treatment of PTSD.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: